161 related articles for article (PubMed ID: 34946271)
21. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Eser A; Toptas T; Kara O; Sezgin A; Noyan-Atalay F; Yilmaz G; Ozgumus T; Pepedil-Tanrikulu F; Kaygusuz-Atagunduz I; Firatli-Tuglular T
Blood Coagul Fibrinolysis; 2016 Jan; 27(1):47-52. PubMed ID: 26258668
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
26. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Burness CB; Keating GM; Garnock-Jones KP
Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
[TBL] [Abstract][Full Text] [Related]
27. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Jarque I; Bernat S; Fernández-Fuertes F; Caparrós I; Soto I; Fernández-Rodríguez A; Bolaños E; Pérez-Rus G; Pascual C; Hernández-Rivas JA; López-Ansoar E; Gómez-Nuñez M; Martínez-Robles V; Olivera P; Yera Cobo M; Peñarrubia MJ; Fernández-Miñano C; de Cabo E; Martínez Badas MP; Perdomo G; García-Frade LJ
Eur J Haematol; 2020 Mar; 104(3):259-270. PubMed ID: 31840311
[TBL] [Abstract][Full Text] [Related]
28. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
[TBL] [Abstract][Full Text] [Related]
30. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
[TBL] [Abstract][Full Text] [Related]
31. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
33. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
Wang J; Dai M; Fu Q; Chen S
Sci Rep; 2021 Mar; 11(1):5459. PubMed ID: 33750817
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
Aleem A; Alotaibi G; Iqbal Z; AlFaifi A
Int J Hematol; 2023 Aug; 118(2):288-291. PubMed ID: 36892804
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
[TBL] [Abstract][Full Text] [Related]
37. Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura.
Sert S; Özdil H; Sünbül M
Turk J Haematol; 2017 Mar; 34(1):107-108. PubMed ID: 27956373
[No Abstract] [Full Text] [Related]
38. Update on eltrombopag for ITP.
Bussel JB
Oncology (Williston Park); 2009 Nov; 23(13):1177-8. PubMed ID: 20043469
[No Abstract] [Full Text] [Related]
39. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
40. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]